KIA
AVDL

Kopp Investment Advisors’s Avadel Pharmaceuticals AVDL Stock Holding History

Kopp Investment Advisors’s Portfolio AVDL Stock Details AVDL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q2 		– Sell
-10,033
Closed -$111K – 64
2016
Q1 		$111K Buy
+10,033
New +$99.7K 0.06% 65
2015
Q4 		– Sell
-17,049
Closed -$278K – 66
2015
Q3 		$278K Sell
17,049
-6,370
-27% -$140K 0.15% 56
2015
Q2 		$496K Buy
23,419
+5,790
+33% +$104K 0.22% 54
2015
Q1 		$317K Buy
17,629
+1,685
+11% +$26.4K 0.14% 62
2014
Q4 		$273K Buy
15,944
+5,625
+55% +$80.3K 0.13% 61
2014
Q3 		$148K Sell
10,319
-715
-6% -$10.3K 0.07% 65
2014
Q2 		$166K Buy
+11,034
New +$133K 0.08% 67

Other funds holding AVDL

BC
Broadfin Capital New York $747M AUM 100.56% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
JHIU
Janus Henderson Investors US Denver, Colorado $122B AUM 18.26% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return
Deutsche Bank
Deutsche Bank Frankfurt Am Main Ge, Germany $344B AUM 42.99% 1-Year Est. Return
JGC
J. Goldman & Co New York $3.87B AUM 46.94% 1-Year Est. Return
FPC
Falcon Point Capital San Francisco, California $11.9M AUM 55.76% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
PCM
Portolan Capital Management Boston, Massachusetts $2.67B AUM 169.09% 1-Year Est. Return

Kopp Investment Advisors's AVDL Position: Q2 2016 in Review

Kopp Investment Advisors sold out of Avadel Pharmaceuticals (AVDL) in Q2 2016, closing a stake of 10,033 shares — an estimated $111K sold.

Kopp Investment Advisors first reported a position in AVDL in Q2 2014 and held it in 7 quarters. The position peaked at $496K in Q2 2015. 84 funds tracked by Wall St. Rank hold AVDL as of Q2 2016.

  • Kopp Investment Advisors reported no remaining Avadel Pharmaceuticals position as of Q2 2016 after selling out during the quarter.
  • Kopp Investment Advisors sold 10,033 Avadel Pharmaceuticals shares in Q2 2016, an estimated $111K.
  • Kopp Investment Advisors first reported a position in Avadel Pharmaceuticals in Q2 2014 and held it in 7 quarters.
  • Kopp Investment Advisors's Avadel Pharmaceuticals position peaked at $496K in Q2 2015.
  • 84 funds tracked by Wall St. Rank held Avadel Pharmaceuticals as of Q2 2016.

Based on Kopp Investment Advisors's 13F filing for Q2 2016, filed 15 Aug 2016.